ALLK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Allakos's tangible book value per share for the quarter that ended in Dec. 2023 was $1.92.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
The historical data trend for Allakos's Tangible Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allakos's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allakos's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Allakos's Price-to-Tangible-Book falls into.
Allakos's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Tangible Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) | / | Shares Outstanding (EOP) |
= | (168.817 | - | 0 | - | 0) | / | 87.75 | |
= | 1.92 |
Allakos's Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as
Tangible Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) | / | Shares Outstanding (EOP) |
= | (168.817 | - | 0 | - | 0) | / | 87.75 | |
= | 1.92 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
Allakos (NAS:ALLK) Tangible Book per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Allakos's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Graham Neil Murray Hamilton | director | 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520 |
Everett Rand Sutherland | director | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Paul Edward Walker | director | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Daniel Janney | director | PO BOX 7414, JACKSON WY 83002 |
Amy L Ladd | director | INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086 |
Craig A. Paterson | officer: Chief Medical Officer | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Margaret Nell Fitzgerald | officer: General Counsel and Secretary | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Steven P James | director | C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Adam Tomasi | officer: COO, CFO and Secretary | ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Robert Alexander | director, officer: President and CEO | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Harlan Baird Radford | officer: Chief Financial Officer | C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125 |
Rasmussen Henrik S Md | officer: Chief Medical Officer | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
John P Mckearn | director, 10 percent owner | 5820 NANCY DRIVE, SAN DIEGO CA 92121 |
Peter A Hudson | 10 percent owner | 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067 |
From GuruFocus
By PRNewswire • 01-23-2024
By sperokesalga sperokesalga • 06-05-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By Business Wire Business Wire • 06-10-2022
By GuruFocusNews GuruFocusNews • 05-06-2022
By Value_Insider Value_Insider • 11-07-2022
By Value_Insider Value_Insider • 11-29-2022
By sperokesalga sperokesalga • 05-09-2023
By Marketwired • 08-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.